FGEN * Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.94 |
| 52 Week High | US$48.00 |
| 52 Week Low | US$6.33 |
| Beta | 0.73 |
| 11 Month Change | 5.44% |
| 3 Month Change | -0.75% |
| 1 Year Change | n/a |
| 33 Year Change | -97.16% |
| 5 Year Change | -98.83% |
| Change since IPO | -97.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| FGEN * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 10.3% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how FGEN * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how FGEN * performed against the MX Market.
Price Volatility
| FGEN * volatility | |
|---|---|
| FGEN * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: FGEN *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine FGEN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 486 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. Fundamentals Summary
| FGEN * fundamental statistics | |
|---|---|
| Market cap | Mex$799.12m |
| Earnings (TTM) | -Mex$2.49b |
| Revenue (TTM) | Mex$3.69b |
0.2x
P/S Ratio-0.3x
P/E RatioIs FGEN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FGEN * income statement (TTM) | |
|---|---|
| Revenue | US$180.02m |
| Cost of Revenue | US$195.17m |
| Gross Profit | -US$15.16m |
| Other Expenses | US$106.64m |
| Earnings | -US$121.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | -8.42% |
| Net Profit Margin | -67.66% |
| Debt/Equity Ratio | -45.1% |
How did FGEN * perform over the long term?
See historical performance and comparison